Welsh John B, Kannard Brian, Nogueira Keith, Kaufman Francine R, Shah Rajiv
Medtronic, Inc., 18000 Devonshire Street, Northridge, CA 91325, USA.
Pediatr Endocrinol Rev. 2010 Aug;7 Suppl 3:413-6.
The CareLink™ (Medtronic, Inc., Northridge, CA) database houses data from continuous glucose monitoring (CGM), insulin pumps, and blood glucose (BG) meters. This study examined CGM usage and its relationship to insulin delivery and glycemia in CareLink users with type 1 diabetes mellitus (T1DM).
Users whose CareLink accounts contained =120 days of pump and glucose readings within a 180-day interval were further selected and stratified based on the frequency of CGM use and adequacy of glycemic control; correlations between these variables were sought.
The proportion of subjects with pre-specified favorable glycemic parameters rose with increasing sensor use (p<0.001). These subjects administered more and smaller boluses, gave a higher proportion of their total daily dose (TDD) of insulin as boluses, and maintained lower TDDs than those with pre-specified less-favorable glycemic parameters (all p<0.001).
A favorable dose effect of CGM use was evident. CGM data facilitates smaller and more frequent bolus dosing, allowing for improved glycemic control.
CareLink™（美敦力公司，加利福尼亚州北岭）数据库存储了来自连续血糖监测（CGM）、胰岛素泵和血糖仪的数据。本研究调查了1型糖尿病（T1DM）患者在CareLink用户中CGM的使用情况及其与胰岛素输注和血糖的关系。
进一步选择CareLink账户在180天间隔内包含≥120天泵和血糖读数的用户，并根据CGM使用频率和血糖控制的充分性进行分层；寻找这些变量之间的相关性。
具有预先指定良好血糖参数的受试者比例随着传感器使用的增加而上升（p<0.001）。这些受试者给予更多且更小的推注剂量，推注剂量占其每日胰岛素总剂量（TDD）的比例更高，并且与具有预先指定较差血糖参数的受试者相比，维持较低的TDD（所有p<0.001）。
CGM使用的良好剂量效应明显。CGM数据有助于进行更小且更频繁的推注给药，从而改善血糖控制。
